Nextcure Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z
Nextcure Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Oxaliplatin in Pancreatic Cancer (Phase 2) using Antibody.
| Asset | Indication | Modality | Stage | Public Note |
|---|---|---|---|---|
| SIM0505 | broad anti-tumor activity and strong cy | Antibody | n/a | Public pipeline row |
| LNCB74 | n/a | Antibody | n/a | Public pipeline row |
| Product Development | n/a | n/a | n/a | Public pipeline row |
| NC318 | n/a | Antibody | Phase 1 | Phase 2 | Public pipeline row |
| Oxaliplatin | Pancreatic Cancer | n/a | Phase 2 | Public pipeline row |
| NC762 | Advanced or Metastatic Solid Tumors | Ovarian Cancer | Non-small Cell Lung Cancer | Breast Cancer | Antibody | Phase 1 | Phase 2 | Public pipeline row |
| SIM0505 for injection | Advanced Solid Tumors | n/a | Phase 1 | Public pipeline row |
Estimated cash runway: Runway 6-12 months.
This is an automated estimate and may differ from company guidance.
| NCT ID | Phase | Status | Enrollment | Primary Completion |
|---|---|---|---|---|
| NCT04430933 | Phase 1 | Phase 2 | WITHDRAWN | n/a | 2022-06-30 |
| NCT03665285 | Phase 1 | Phase 2 | COMPLETED | 109 | 2023-04-11 |
| NCT04875806 | Phase 1 | Phase 2 | TERMINATED | 40 | 2024-01-30 |
| NCT06792552 | Phase 1 | RECRUITING | 414 | 2028-02 |
| NCT06941857 | Phase 2 | RECRUITING | 20 | 2030-09 |
Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.
Get the weekly biotech catalyst watchlistThis page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.